H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Arbutus Biopharma to $6 from $7.50 and keeps a Buy rating on the shares post the Q3 results.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABUS: